Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (avaa uuden ikkunan)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Lähde‎: Ann Intern Med 2008;148(12):939-55.

Arkistoitu‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (avaa uuden ikkunan)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (avaa uuden ikkunan)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Lähde‎: Am J Hematol 2000;64(1):26-31.

Arkistoitu‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (avaa uuden ikkunan)

Hydroxyurea for the treatment of sickle cell anemia. (avaa uuden ikkunan)

Platt OS.

Lähde‎: N Engl J Med 2008;358(13):1362-9.

Arkistoitu‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (avaa uuden ikkunan)

Clinical effectiveness of decitabine in severe sickle cell disease. (avaa uuden ikkunan)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Lähde‎: Br J Haematol 2008;141(1):126-9.

Arkistoitu‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (avaa uuden ikkunan)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (avaa uuden ikkunan)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Lähde‎: Blood 2010;115(12):2354-63.

Arkistoitu‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (avaa uuden ikkunan)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (avaa uuden ikkunan)

Hirst C, Owusu-Ofori S.

Lähde‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Arkistoitu‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (avaa uuden ikkunan)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (avaa uuden ikkunan)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Lähde‎: Lancet Haematol 2021;8(5):e323-33.

Arkistoitu‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (avaa uuden ikkunan)

Sickle cell disease. (avaa uuden ikkunan)

Meremikwu MM, Okomo U.

Lähde‎: BMJ Clin Evid 2011;02:2402.

Arkistoitu‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (avaa uuden ikkunan)

A phase 3 trial of l-glutamine in sickle cell disease. (avaa uuden ikkunan)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Lähde‎: N Engl J Med 2018;379(3):226-35.

Arkistoitu‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (avaa uuden ikkunan)

Malaria chemoprophylaxis in sickle cell disease. (avaa uuden ikkunan)

Oniyangi O, Omari AA.

Lähde‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Arkistoitu‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (avaa uuden ikkunan)